National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Isr Med Assoc J. 2022 Mar;24(3):179-182.
Pulmonary embolism (PE) is very common in cancer patients and is a marker of increased mortality in these patients. Treatment is associated with increased rates of recurrent thrombosis and bleeding and has undergone significant change in the last years with the increasing use of direct oral anticoagulants. Diagnosis of PE and risk stratification is possible with minor changes to existing risk scores. Thrombolytic therapy should be considered in appropriate patients.
肺栓塞(PE)在癌症患者中非常常见,是这些患者死亡率增加的标志。治疗与复发性血栓形成和出血的发生率增加有关,并且随着直接口服抗凝剂的使用增加,近年来发生了重大变化。PE 的诊断和风险分层可以通过对现有风险评分进行微小改变来实现。在适当的患者中应考虑溶栓治疗。